$ATTO

Redmile Group, LLC purchased $6.8M of ATTO (indirect holdings)

Redmile Group, LLC purchased 400,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($6.80M total) on 2026-08-06.

Original reporting
SEC EDGAR · Redmile Group, LLC
Published Aug 8, 2026, 1:47 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 2:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATTO
Neutral
low confidence
Mentioned
$ATTO
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATTONeutralLow
01

Why it matters

A 10% owner (Redmile Group, LLC) reported an open-market purchase of 400,000 shares at $17.00, totaling $6.8M, with holdings after the trade of 1,182,854 shares.

02

Market read

Traders may view the transaction as mild positive sentiment, but it does not provide new fundamentals or a near-term catalyst.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the text does not clarify intent, timing constraints, or whether other related transactions occurred.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-07 after 2026-08-06 purchase

Background

This is an SEC Form 4 insider transaction disclosure for Attovia Therapeutics, Inc. (ATTO).

Company-level read

Ticker impact

$ATTONeutralLow confidence
Context

Redmile Group, LLC, a 10% owner, bought 400,000 ATTO shares in an open-market transaction for $6.8M on 2026-08-06.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than a new operating catalyst.

Evidence & confidence

Form 4 shows a large indirect purchase, but there is no accompanying guidance, deal, or operational change disclosed in the text.

Market effects

Minimal, as this is a single-issuer Form 4 transaction without sector-wide information.

None indicated.

None indicated.

Counterpoint

A large-holder purchase can reflect diversification, tax planning, or pre-existing arrangements rather than a new bullish thesis.

Key entities

  • Attovia Therapeutics, Inc.

    Subject of the Form 4 disclosure; ticker ATTO.

  • Redmile Group, LLC

    Reporter of the indirect open-market purchase.

Related articles

$ATTOMedAI 8/10

Attovia raises $265m in upsized IPO for trials

Attovia filed an amended S-1 for an upsized IPO raising about $265.1 million in net proceeds, up from roughly $182.4 million earlier. Funds will support two Phase II trials starting in H1 2027 for ATTO-1310, an engineered biologic targeting IL-31 for chronic pruritic diseases. The filing cites Phase Ib results and prior funding rounds.

$ATTOMedAI 8/10

Attovia Therapeutics prices IPO at $17 per share on Nasdaq

Attovia Therapeutics (Nasdaq: ATTO) priced its IPO at $17.00 per share, selling 17.0 million shares for expected gross proceeds of about $289.0 million, with a 30-day option for up to 2.55 million more shares. The stock is set to start trading Aug. 5, 2026, under ATTO. Joint bookrunners include Morgan Stanley, Leerink, Citigroup, and RBC.

Redmile Group, LLC purchased $6.8M of ATTO (indirect holdings) — alphai